b'PROLONGED PFSPROVEN TO TREAT ADULTSDESIGNED TO STREAMLINEIN GEP-NETS WITH CARCINOID SYNDROME PREPARATION AND ADMINISTRATION53 15% %reduction in risk ofabsolute reduction inSingle-dose, ready-to-use,death or diseasethe number of daysprefilled syringenoprogression 3 rescue SSA was used 4 reconstitution required 1Join over 5800 healthcare providers who have prescribed Somatuline Depot to help patients with GEP-NETs and carcinoid syndrome since 2017 5 **Based on insurance claims during November 2017October 2020; subject to change without notice.FOR USE WITHVeterans Administration& Department of DefenseWarnings and Precautions (continued) Cardiovascular Abnormalities (continued) In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. Care should be taken when initiating treatment in patients with bradycardia.Most Common Adverse Reactions GEP-NETs: Adverse reactions in 10% of patients who received SOMATULINE DEPOT were abdominal pain (34%), musculoskeletal pain (19%), vomiting (19%), headache (16%), injection site reaction (15%), hyperglycemia (14%), hypertension (14%), and cholelithiasis (14%). Carcinoid Syndrome: Adverse reactions occurring in the carcinoid syndrome trial were generally similar to those in the GEP-NET trial. Adverse reactions in 5% of patients who received SOMATULINE DEPOT and at least 5% greater than placebo were headache (12%), dizziness (7%) and muscle spasm (5%).Drug Interactions:SOMATULINE DEPOT may decrease the absorption of cyclosporine (dosage adjustment may be needed); increase the absorption of bromocriptine; and require dosage adjustment for bradycardia-inducing drugs (e.g., beta-blockers).Special Populations Lactation: Advise women not to breastfeed during treatment and for 6 months after the last dose.To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at1-800-FDA-1088 or www.fda.gov/medwatch.References: 1. Somatuline Depot (lanreotide) Injection [Prescribing Information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc; June 2019. 2. Data on file. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; 2018. This study has been funded by Ipsen. 3. Caplin ME, Pavel M, wika JB, et al; for the CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233. 4. Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA; on behalf of the ELECT Study Group. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, place-bo-controlled trial. Endocr Pract. 2016;22(9):1068-1080. 5. Ipsen data on file. IQVIA patient claims, November 2017-October 2020. Somatuline Depot is a registered trademark of Ipsen Pharma S.A.S.2021 Ipsen Biopharmaceuticals, Inc. November 2021. SMD-US-005370'